Studies on lactoferrin nanoparticles of gambogic acid for oral delivery

Drug Delivery

Volumn 20, Issue 2, 2013, Pages 86-93

  Zhang, Zhen Hai ^a,b   Wang, Xiao Pan ^a   Ayman, Waddad Y ^a   Munyendo, Were L L ^a   Lv, Hui Xia ^a   Zhou, Jian Ping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Jiangsu Province Academy of Traditional Chinese Medicine   (China)

Author keywords

Anti tumor activity; Gambogic acid; Lactoferrin; Nanoparticles; Oral administration

Indexed keywords

GAMBOGIC ACID; LACTOFERRIN; NANOPARTICLE;

ACTIVE TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DIFFUSION; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE PERFUSION; MALE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SLOW DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CALORIMETRY, DIFFERENTIAL SCANNING; CELL PROLIFERATION; DRUG CARRIERS; FEASIBILITY STUDIES; HEP G2 CELLS; HUMANS; INTESTINAL ABSORPTION; LACTOFERRIN; MALE; MEDICINE, CHINESE TRADITIONAL; MICE; MICE, INBRED ICR; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR STRUCTURE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SARCOMA 180; SOLUBILITY; SURFACE PROPERTIES; XANTHONES;

EID: 84875726647     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.766781     Document Type: Article

References (41)

1. Adlerova1 L, Bartoskova1 A, Faldyna M. (2008). Lactoferrin: a review. Veter Med 53:457-68.
2. Amet N, Wang W, Shen WC. (2010). Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats. J Control Release 141:177-82.
3. Bai Y, Ann DK, Shen WC. (2005). Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent. Proc Natl Acad Sci USA 102:7292-6.
4. Brines RD, Brock JH. (1983). The effect of trypsin and chymotrypsin on the in vitro antimicrobial and iron-binding properties of lactoferrin in human milk and bovine colostrum. Unusual resistance of human apolactoferrin to proteolytic digestion. Biochim Biophys Acta 759:229-35.
5. Brock JH, Arzabe F, Lampreave F, Pineiro A. (1976). The effect of trypsin on bovine transferrin and lactoferrin. Biochim Biophys Acta 446:214-25.
6. Chakraborty C, Sarkar B, Hsu CH, et al. (2009). Future prospects of nanoparticles on brain targeted drug delivery. J Neurooncol 93:285-6.
7. Cox TM, Mazurier J, Spik G, et al. (1979). Iron bonding proteins and influx of iron across the duodenal brush border. Evidence for specific lactotransferrin receptors in the human intestine. Biochim Biophys Acta 588:120-8.
8. Des Rieux A, Fievez V, Garinot M, et al. (2006). Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 116:1-27.
9. Fagerholm U, Johansson M, Lennernas H. (1996). Comparison between permeability coefficients in rat and human jejunum. Pharm Res 13:1336-42.
10. Faucheux BA, Nillesse N, Damier P, et al. (1995). Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. PNAS 92:9603-7.
11. Fu Q, Sun J, Zhang WP, et al. (2009). Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Patents Anti-Cancer Drug Discov 4:262-72.
12. Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL. (2001). The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590-8.
13. Gu H, Rao S, Zhao J. (2009). Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. J Cancer Res Clin Oncol 135:1777-82.
14. Guo QL, Zhao L, Wu ZQ, et al. (2003). Effect of gambogic acid on the hemopoietic and immune functions in experimental animals. Chin J Nat Med 4:229-32.
15. Guo QL, You QD, Wu ZQ, et al. (2004). General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacol Sin 25:769-74.
16. Hao K, Liu XQ, Wang GJ. (2005). Pharmacokinetics of gambogic acid in rats. J China Pharma Univ 36:338-41.
17. Hao K, Liu XQ, Wang GJ, Zhao XP. (2007a). Pharmacokinetics, tissue distribution and excretion of gambogic acid in rats. Eur J Drug Metab Pharmacokinet 32:63-8.
18. Hao K, Zhao XP, Liu XQ, Wang GJ. (2007b). Determination of gambogic acid in dog plasma by high-performance liquid chromatography for a pharmacokinetic study. Biomed Chromatogr 21:279-83.
19. Hong M, Zhu S, Jiang Y, et al. (2010). Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparti-cles. J Control Release 141:22-9.
20. Jiang Y, Jiang X, Law K, et al. (2011). Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-beta-cyclodextrin and safety evaluation. Int J Pharm 415:252-8.
21. Kaili H, Jingwei L, Yehong S, et al. (2009). Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release 134:55-61.
22. Kim TH, Jiang HH, Youn YS, et al. (2011). Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 403:285-91.
23. Leveugle B, Mazurier J, Legrand D, et al. (1993). Lactotransferrin binding to its platelet receptor inhibits platelet aggregation. Eur J Biochem 213:1205-11.
24. Li H, Huo M, Zhou J, et al. (2010). Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. J Pharm Sci 99:4543-53.
25. Liu Q, Li R, Zhu Z, et al. (2012). Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles. Int J Pharm 430:350-8.
26. Montalar M, Nalda-Molina R, Rodriguez-Ibanez M, et al. (2003). Kinetic modeling of triamterene intestinal absorption and its inhibition by folic acid and methotrexate. J Drug Target 11:215-23.
27. Nillesse N, Pierce A, Lecocq M, et al. (1994). Expression of the lactotransferrin receptor during the differentiation process of the megakaryocyte Dami cell line. Biol Cell 82:149-59.
28. Qu G, Zhu X, Zhang C, Ping Q. (2009). Modified chitosan derivative micelle system for natural anti-tumor product gambogic acid delivery. Drug Deliv 16:363-70.
29. Shofner JP, Phillips MA, Peppas NA. (2010). Cellular evaluation of synthesized insulin/transferrin bioconjugates for oral insulin delivery using intelligent complexation hydrogels. Macromol Biosci 10:299-306.
30. Susana A, Chávez G, Arévalo-Gallegos S, Rascón-Cruz Q. (2009). Lactoferrin: structure, function and application. Int J Antimicrob 33:301.e1-8.
31. Sutton SC, Rinaldi MTS, Vukovinsky KE. (2001). Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model. AAPS Pharm Sci 3:93-7.
32. Suzuki YA, Lopez V, Lönnerdal B. (2005). Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci 62:2560-75.
33. 4 nanoparticles. Int J Nanomed 6:1929-35.
34. Wang J, Hu Y, Li L, et al. (2010). Indomethacin-5-fluorouracil-methyl ester dry emulsion: a potential oral delivery system for 5-fluorouracil. Drug Dev Ind Pharm 36:647-56.
35. Wang J, Zhao L, Hu Y, et al. (2009). Studies on chemical structure modification and biology of a natural product, gambogic acid (I): synthesis and biological evaluation of oxidized analogues of gambogic acid. Eur J Med Chem 44:2611-20.
36. Wang XP, Lv HX, Waddad AY, et al. (2012). Studies on intestinal absorption kinetics of gambogic acid by rat single pass perfusion in situ. China J Chin Materia Medica 37:2079-83.
37. Yi T, Yi Z, Cho SG, et al. (2008). Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res 68:1843-50.
38. Yoav DL. (2010). Milk proteins as vehicles for bioactives. Curr Opin Colloid Interf Sci 15:73-83.
39. Yu J, Guo QL, You QD, et al. (2007). Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphoryla-tion of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 28:632-8.
40. Zakeri MP, Valizadeha H, Tajerzadehc H, et al. (2007). Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharma Sci 10:368-79.
41. Zhang W, Shi Y, Chen Y, et al. (2010). Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur J Pharm Biopharm 75:341-53.